Dr. John Walshe first described the use of penicillamine in Wilson's disease in 1956. He had discovered the compound in the urine of patients (including himself) who had taken penicillin, and experimentally confirmed that it increased urinary copper excretion by chelation. He had initial difficulty convincing several world experts of the time (Drs Denny Brown and Cumings) of its efficacy, as they held that Wilson's disease was not primarily a problem of copper homeostasis but of amino acid metabolism, and that dimercaprol should be used as a chelator. Later studies confirmed both the copper-centered theory and the efficacy of D-penicillamine. Walshe also pioneered other chelators in Wilson's such as triethylene tetramine, 2HCl, and tetrathiomolybdate.
Penicillamine has been used in rheumatoid arthritis since the first successful case in 1964.
^ abPeisach, J.; Blumberg, W. E. (1969). "A mechanism for the action of penicillamine in the treatment of Wilson's disease". Molecular pharmacology5 (2): 200–209. PMID4306792. edit
^ abParker, C. W.; Shapiro, J.; Kern, M.; Eisen, H. N. (1962). "Hypersensitivity to penicillenic acid derivatives in human beings with penicillin allergy". The Journal of experimental medicine115 (4): 821–838. PMC2137514. PMID14483916. edit
^ abcdCamp, A. V. (1977). "Penicillamine in the treatment of rheumatoid arthritis". Proceedings of the Royal Society of Medicine70 (2): 67–69. PMC1542978. PMID859814. edit
^ abRosenberg, L. E.; Hayslett, J. P. (1967). "Nephrotoxic Effects of Penicillamine in Cystinuria". JAMA: the Journal of the American Medical Association201 (9): 698. doi:10.1001/jama.1967.03130090062021.edit
^Steen, V. D.; Medsger Jr, T. A.; Rodnan, G. P. (1982). "D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): A retrospective analysis". Annals of internal medicine97 (5): 652–659. PMID7137731. edit
^Grasedyck, K. (1988). "D-penicillamine--side effects, pathogenesis and decreasing the risks". Zeitschrift fur Rheumatologie. 47 Suppl 1: 17–19. PMID3063003. edit
^ abFishel, B.; Tishler, M.; Caspi, D.; Yaron, M. (1989). "Fatal aplastic anaemia and liver toxicity caused by D-penicillamine treatment of rheumatoid arthritis". Annals of the rheumatic diseases48 (7): 609–610. PMC1003826. PMID2774703. edit
^Chalmers, A.; Thompson, D.; Stein, H. E.; Reid, G.; Patterson, A. C. (1982). "Systemic lupus erythematosus during penicillamine therapy for rheumatoid arthritis". Annals of internal medicine97 (5): 659–663. PMID6958210. edit
^Bolognia, Jean; et al (2007). Dermatology. Philadelphia: Elsevier. ISBN1-4160-2999-0.2nd edition.